Alzheimer’s Society Comment On Research Into Impact Of Vitamin D On Brain Performance1
Alzheimer’s Society Comment On Research Into Impact Of Vitamin D On Brain Performance
A study of 3,133 men from a variety of test centres across Europe has shown that lower 25 (OH) D levels (vitamin D levels) were associated with poorer brain performance (in middle aged and older men). The study looked at a number of cognitive function tests with only one being linked to vitamin D statistically. The study did not look at cognitive function in women.
Painkillers May Not Protect Against Dementia
Title: Painkillers May Not Protect Against Dementia
Category: Health News
Created: 4/23/2009 2:00:00 AM
Last Editorial Review: 4/23/2009
Special Protein Helps Maintain An Efficient Brain
The instruction manual for maintaining an efficient brain may soon include a section on synaptotagmin-IV (Syt-IV), a protein known to influence learning and memory, thanks to a study by University of Wisconsin-Madison researchers. The study showed that Syt-IV keeps the strength of synapses - connections between nerve cells where communication occurs - within a useful range of neither too strong nor too weak.
Rapid Weight Loss in Seniors Signals Higher Dementia Risk
Title: Rapid Weight Loss in Seniors Signals Higher Dementia Risk
Category: Health News
Created: 5/20/2009 2:00:00 AM
Last Editorial Review: 5/20/2009
Why Chimps, Monkeys Don’t Develop Alzheimer’s
Title: Why Chimps, Monkeys Don’t Develop Alzheimer’s
Category: Health News
Created: 5/26/2009 7:00:00 AM
Last Editorial Review: 5/26/2009
New Data Show Cost Savings Achieved By Treating Mild And Moderate Alzheimer’s Patients With Aricept(R)
Researchers attending the annual meeting of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR), heard today that prescribing Aricept (donepezil hydrochloride) as soon as patients are diagnosed with either mild or moderate Alzheimer’s disease saves the NHS money. The findings contradict the recommendation by NICE that these medicines are not cost effective in the early stages of the disease, a decision that has been the subject of much recent debate.
Early Alzheimer’s Disease May Be Identified By Automated Analysis Of MR Images
Analyzing MRI studies of the brain with software developed at the Martinos Center for Biomedical Imaging at Massachusetts General Hospital (MGH) may allow diagnosis of Alzheimer’s disease and of mild cognitive impairment, a lesser form of dementia that precedes the development of Alzheimer’s by several years.
Revealing A Surprising Link Between Diabetes And Alzheimer’s Disease
Blindness, heart disease, nerve damage, and kidney failure are not the only complications facing the nation’s estimated 24 million people with diabetes. Although not widely known, those with the disease face up to double the risk of developing Alzheimer’s disease (AD) than non-diabetics, according to an article scheduled for the May 18 issue of Chemical & Engineering News, ACS’ weekly newsmagazine.
Satoris Launches 3 New Blood Tests To Help Researchers Identify Alzheimer’s And Develop Drug Therapies
Satoris, Inc., a California-based molecular diagnostics company, announced today the launch of three research-use tests - two panels of plasma biomarkers shown to be significant in the neurodegenerative disease process, and a dementia discrimination panel. Specifically for use by Alzheimer’s researchers and by pharmaceutical companies developing new Alzheimer’s therapies, the panels are available now as a testing service.
Health Tip: Warding Off Age-Related Memory Loss
Title: Health Tip: Warding Off Age-Related Memory Loss
Category: Health News
Created: 5/20/2009 9:41:00 AM
Last Editorial Review: 5/20/2009
Both Phase III Pivotal Trials Begin Enrollment In May 2009; Reinforces Lilly’s Commitment To Alzheimer’s Disease And Biotech Product Research
Eli Lilly and Company (NYSE: LLY) announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer’s disease.
Mixed Neurodegenerative Disorders Are Emerging From The Shadows
Many cases of age-related neurodegenerative disease fall into the gray zone between big, defined diseases - Alzheimer’s or Parkinson’s, for example. Their diagnostic accuracy is low, researchers agree. That’s a problem, because mixed disease is not only common, but also quite different in its course from pathologically ‘pure’ disease. (Mixed disease is often worse.) But there’s also excitement and opportunity.
Blanchette Rockefeller Neurosciences Institute And Inverness Medical Innovations To Develop Commercial Test To Detect Early Alzheimer’s Disease
The Blanchette Rockefeller Neurosciences Institute (BRNI) and Inverness Medical Innovations, Inc. (Inverness, NYSE: IMA) of Waltham, Massachusetts, a global leader in rapid diagnostics and health management, announced today that they will work together to further develop and commercialize a diagnostic test for Alzheimer’s disease first discovered by scientists at BRNI. The BRNI test, once fully commercialized, could dramatically change the time and way that the disease is treated.